Innate Pharma Net Worth
Innate Pharma Net Worth Breakdown | IPHA |
Innate Pharma Net Worth Analysis
Innate Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Innate Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Innate Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Innate Pharma's net worth analysis. One common approach is to calculate Innate Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Innate Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Innate Pharma's net worth. This approach calculates the present value of Innate Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Innate Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Innate Pharma's net worth. This involves comparing Innate Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Innate Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Innate Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Innate Pharma's net worth research are outlined below:
| Innate Pharma generated a negative expected return over the last 90 days | |
| Innate Pharma has high historical volatility and very poor performance | |
| Innate Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 12.62 M. Net Loss for the year was (49.47 M) with loss before overhead, payroll, taxes, and interest of (31.86 M). | |
| Innate Pharma currently holds about 123.35 M in cash with (6.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.54. |
Innate Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Innate Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Innate Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Innate Pharma Target Price Consensus
Innate target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Innate Pharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 3 | Buy |
Most Innate analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Innate stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Innate Pharma, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationInnate Pharma Target Price Projection
Innate Pharma's current and average target prices are 2.15 and 7.84, respectively. The current price of Innate Pharma is the price at which Innate Pharma is currently trading. On the other hand, Innate Pharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Innate Pharma Market Quote on 3rd of August 2025
Target Price
Analyst Consensus On Innate Pharma Target Price
Know Innate Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Innate Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Innate Pharma backward and forwards among themselves. Innate Pharma's institutional investor refers to the entity that pools money to purchase Innate Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Exchange Traded Concepts, Llc | 2025-03-31 | 62.8 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 43.5 K | Citadel Advisors Llc | 2025-03-31 | 24.3 K | Millennium Management Llc | 2025-03-31 | 15.3 K | Ubs Group Ag | 2025-03-31 | 9 K | Gamma Investing Llc | 2025-06-30 | 3.5 K | Rhumbline Advisers | 2025-03-31 | 675 | Barclays Plc | 2025-03-31 | 307 | Optiver Holding B.v. | 2025-03-31 | 101 | Tower Research Capital Llc | 2025-03-31 | 3.0 | Steward Partners Investment Advisory, Llc | 2025-03-31 | 0.0 |
Follow Innate Pharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 198.15 M.Market Cap |
|
Project Innate Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.45) | (0.42) | |
| Return On Capital Employed | (0.76) | (0.72) | |
| Return On Assets | (0.45) | (0.42) | |
| Return On Equity | (5.60) | (5.32) |
When accessing Innate Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Innate Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Innate Pharma's profitability and make more informed investment decisions.
Please note, the presentation of Innate Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Innate Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Innate Pharma's management manipulating its earnings.
Evaluate Innate Pharma's management efficiency
Innate Pharma has return on total asset (ROA) of (0.2252) % which means that it has lost $0.2252 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6291) %, meaning that it created substantial loss on money invested by shareholders. Innate Pharma's management efficiency ratios could be used to measure how well Innate Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.42. The current year's Return On Capital Employed is expected to grow to -0.72. At present, Innate Pharma's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 130.6 M, whereas Non Current Assets Total are forecasted to decline to about 24.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.11 | 0.10 | |
| Tangible Book Value Per Share | 0.11 | 0.10 | |
| Enterprise Value Over EBITDA | (2.37) | (2.25) | |
| Price Book Value Ratio | 17.71 | 18.59 | |
| Enterprise Value Multiple | (2.37) | (2.25) | |
| Price Fair Value | 17.71 | 18.59 | |
| Enterprise Value | 162.1 M | 154 M |
Examining the leadership quality of Innate Pharma offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Enterprise Value Revenue 9.6096 | Revenue | Quarterly Revenue Growth (0.64) | Revenue Per Share | Return On Equity |
Innate Pharma Earnings Estimation Breakdown
The calculation of Innate Pharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Innate Pharma is estimated to be -0.22075 with the future projection ranging from a low of -0.22075 to a high of -0.22075. Please be aware that this consensus of annual earnings estimates for Innate Pharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.22 Lowest | Expected EPS | -0.22 Highest |
Innate Pharma Earnings Projection Consensus
Suppose the current estimates of Innate Pharma's value are higher than the current market price of the Innate Pharma stock. In this case, investors may conclude that Innate Pharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Innate Pharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 4 | 58.9% | -0.3 | -0.22075 | -0.7 |
Innate Pharma Earnings per Share Projection vs Actual
Actual Earning per Share of Innate Pharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Innate Pharma predict the company's earnings will be in the future. The higher the earnings per share of Innate Pharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Innate Pharma Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Innate Pharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Innate Pharma should always be considered in relation to other companies to make a more educated investment decision.Innate Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Innate Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-03-27 | 2024-12-31 | -0.4 | -0.3 | 0.1 | 25 | ||
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2023-09-14 | 2023-06-30 | -0.14 | 0.02 | 0.16 | 114 | ||
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2022-04-03 | 2022-03-31 | -0.17 | -0.16 | 0.01 | 5 | ||
2022-03-24 | 2021-12-31 | 0 | -0.66 | -0.66 | 0 | ||
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2021-04-26 | 2021-03-31 | 0.05 | -0.18 | -0.23 | 460 | ||
2021-03-18 | 2020-12-31 | -0.09 | -0.176 | -0.086 | 95 | ||
2020-11-17 | 2020-09-30 | -0.0945 | -0.0945 | 0.0 | 0 | ||
2020-09-08 | 2020-06-30 | -0.08 | -0.0827 | -0.0027 | 3 | ||
2020-05-12 | 2020-03-31 | 0 | -0.0736 | -0.0736 | 0 | ||
2020-03-10 | 2019-12-31 | -0.18 | -0.18 | 0.0 | 0 | ||
2019-11-13 | 2019-09-30 | -0.09 | 0.0445 | 0.1345 | 149 | ||
2019-09-13 | 2019-06-30 | -0.09 | -0.0884 | 0.0016 | 1 | ||
null | null | null | null | null | 0 | ||
2018-11-15 | 2018-09-30 | 0 | 0.0791 | 0.0791 | 0 | ||
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 |
Innate Pharma Corporate Management
| Odile Belzunce | Vice Operations | Profile | |
| Marc Bonneville | Founder | Profile | |
| Jean Fourni | Founder | Profile | |
| Henry MSc | Vice Communication | Profile | |
| DVM MBA | VP Founder | Profile | |
| Sonia MD | Executive Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.70) | Revenue Per Share | Quarterly Revenue Growth (0.64) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.